The Shelton Green Alpha Fund is up more than 100% year-to-date and is among the best-performing funds of 2020 – and a big reason for its outperformance is its biotech holdings, especially Moderna which the fund’s co-managers bought in 2019. In today’s article, those co-managers share three other biotech firms they are bullish on because of their potential to solve future disease outbreaks and the amount of intellectual property they own. They also share why they believe Moderna is still a good buy even after its massive run-up this year. For more, CLICK HERE.